|Awarded On||August 24, 2018|
|Title||STOP-HCC Expansion Grant|
|Award Mechanism||Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Mamta Jain|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Hepatocellular cancer (HCC) is the fastest growing cancer in Texas. The age-adjusted incidence of liver cancer in Texas is the highest in the U.S. The majority of HCC is due to viral hepatitis, primarily hepatitis C (HCV) in the US and hepatitis B virus (HBV) globally. HCV is curable and HBV is a vaccine-preventable disease. To reduce HCC burden, we are targeting counties in North, South and West Texas with high HCC incidence and significant need to increase prevention through HCV and HBV screening, immunization, and treatment.
A robust primary care-based HCV screening program for baby boomers (BBs; born 1945-65) and HBV/HCV case finding other high risk groups based on national and exp...